| Theme | New Perspectives of Molecular Biomarker in Dialysis Therapy | |
|---|---|---|
| Title | Biomarkers of gastrointestinal disease | |
| Publish Date | 2011/04 | |
| Author | Yasushi Hamaya | Department of Molecular Diagnosis, Hamamatsu University School of Medicine |
| Author | Mitsushige Sugimoto | Center for Clinical Research, Hamamatsu University School of Medicine |
| Author | Shigeru Kanaoka | Department of Molecular Diagnosis, Hamamatsu University School of Medicine |
| Author | Takahisa Furuta | Center for Clinical Research, Hamamatsu University School of Medicine |
| Author | Mutsuhiro Ikuma | First Department of Medicine, Hamamatsu University School of Medicine |
| [ Summary ] | Helicobacter pylori infection is a major risk factor for development of gastric cancer and peptic ulcers. Therefore, it is important to correctly diagnose H. pylori infections. Non-invasive methods, such as the urea breath test or detection of stool antigens and serum anti-H. pylori antibodies are recommended to detect H. pylori infection in patients receiving ongoing hemodialysis treatment. Moreover, because patients treated with hemodialysis are at a higher risk of developing some types of cancer, such as gastric cancer, new screening methods have been developed. These detect polymorphisms of inflammatory cytokine genes (i.e., IL-B-511 and TNF-A-857/-863/-1031) and renin-angiotensin system genes (i.e., CMA/B and AGT-20). Methods to detect fecal COX-2 and MMP-7 mRNA (fecal RNA testing) for colorectal cancer, are being developed. | |